{"id":5495,"date":"2017-01-05T11:52:11","date_gmt":"2017-01-05T16:52:11","guid":{"rendered":"https:\/\/medicarereport.org\/?p=5495"},"modified":"2017-01-05T11:52:11","modified_gmt":"2017-01-05T16:52:11","slug":"where-does-alzheimers-treatment-go-from-here","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=5495","title":{"rendered":"Where Does Alzheimer&#8217;s Treatment Go From Here?"},"content":{"rendered":"<p>(By Bret Stetka for NPR)<\/p>\n<p>In a disappointment to Alzheimer&#8217;s patients and researchers, drugmaker Eli Lilly said in late November that a clinical trial of solanezumab, an experimental medication to treat the degenerative neurological condition, had failed. <a href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/12\/29\/506592761\/where-does-alzheimer-s-treatment-go-from-here?utm_campaign=KHN%3A+Daily+Health+Policy+Report&amp;utm_source=hs_email&amp;utm_medium=email&amp;utm_content=40134880&amp;_hsenc=p2ANqtz-9Rr-Ya54bgqgGDCJh92PgGQ2pAixWI3PDl8yacdCNm-Dgi-75Ie8TGhfP0GIi_Jz8x3mhHxXMP4qdtQfa3R7jI4ZZs3A&amp;_hsmi=40134880\" target=\"_blank\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-3902\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"NPR logo\" width=\"152\" height=\"55\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 152px) 100vw, 152px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Bret Stetka for NPR) In a disappointment to Alzheimer&#8217;s patients and researchers, drugmaker Eli Lilly said in late November<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18,15],"tags":[],"class_list":["post-5495","post","type-post","status-publish","format-standard","hentry","category-aging","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/5495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5495"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/5495\/revisions"}],"predecessor-version":[{"id":5496,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/5495\/revisions\/5496"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}